Family Office Of America (FOFA) Net Income towards Common Stockholders (2021 - 2026)
Family Office Of America (FOFA) reported Net Income towards Common Stockholders of $209049.0 for Q1 2026, up 302.33% on a YoY basis from $51959.6 in Q1 2025, and up 185.94% sequentially from -$243255.0 in Q4 2025.
Family Office Of America (FOFA) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Family Office Of America (FOFA) has 6 years of Net Income towards Common Stockholders data on file, last reported at $209049.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 302.33% year-over-year to $209049.0; the trailing twelve-month figure through Mar 2026 stood at -$180378.0 (up 3.87% YoY), and the FY2025 full-year result was -$492748.0, down 390.37% from the prior year.
- Net Income towards Common Stockholders climbed to $209049.0 in Q1 2026, from -$243255.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $943223.0 in Q4 2023 to a low of -$1.6 million in Q2 2023.
- A 5-year average of -$124101.1 and a median of -$79811.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders surged 601.04% in 2023 and slumped 699.65% in 2025, its largest moves.
- Tracing FOFA's Net Income towards Common Stockholders over 5 years: stood at -$188254.0 in 2022, then surged by 601.04% to $943223.0 in 2023, then plunged by 103.23% to -$30420.0 in 2024, then slumped by 699.65% to -$243255.0 in 2025, then jumped by 185.94% to $209049.0 in 2026.
- Business Quant data shows FOFA's Net Income towards Common Stockholders at $209049.0 in Q1 2026, -$243255.0 in Q4 2025, and -$50944.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Family Office Of America | 27.22 Mn | 26.88 Mn | 783,126.00 | 209,049.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,049.00 |
| Dec 31, 2025 | -243,255.00 |
| Sep 30, 2025 | -50,944.00 |
| Jun 30, 2025 | -95,228.00 |
| Mar 31, 2025 | -103,321.00 |
| Dec 31, 2024 | -30,420.00 |
| Sep 30, 2024 | -22,676.00 |
| Jun 30, 2024 | -31,228.00 |
| Mar 31, 2024 | -16,160.00 |
| Dec 31, 2023 | 943,223.00 |
| Sep 30, 2023 | -28,572.00 |
| Jun 30, 2023 | -1.64 Mn |
| Mar 31, 2023 | -79,811.00 |
| Dec 31, 2022 | -188,254.00 |
| Sep 30, 2022 | -126,659.00 |
| Jun 30, 2022 | -510,529.00 |
| Mar 31, 2022 | -95,073.00 |
| Dec 31, 2021 | -386,442.00 |
| Sep 30, 2021 | -518,866.00 |
| Jun 30, 2021 | -622,777.00 |